feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouIndiaIndia
You
bookmarksYour BookmarkshashtagYour Topics
Trending
trending

Andaman earthquake strikes sea

trending

SEBI cautions digital gold investments

trending

Mumbai stray dog shelter shortage

trending

Djokovic withdraws from ATP Finals

trending

Real Madrid faces Rayo Vallecano

trending

Man City vs Liverpool

trending

Arsenal leads Premier League race

trending

PSG aims to stretch unbeaten

trending

Thuram pushes Inter vs Lazio

Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2025 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / Subtle Dementia Signs That Shouldn't Be Ignored

Subtle Dementia Signs That Shouldn't Be Ignored

13 Nov

•

Summary

  • Difficulty with language, navigation, and completing familiar tasks
  • Abrupt personality or mood changes can signal dementia
  • New drugs show promise in slowing cognitive decline
Subtle Dementia Signs That Shouldn't Be Ignored

As of November 2025, dementia remains a significant health concern, affecting an estimated 6.7 million Americans over the age of 65. While memory loss and confusion are well-known symptoms of dementia and Alzheimer's disease, the most common form of dementia, experts caution that there are more subtle signs that are often overlooked.

According to neurologists, early warning signs can include difficulty with language, such as word-finding problems, incorrect sentence construction, and trouble with self-expression. Additionally, changes in visual and spatial skills, like getting lost in previously familiar routes, can also be an early indicator. Personality and mood shifts without an underlying explanation are also red flags that should not be ignored.

Fortunately, recent breakthroughs in medical science offer hope for individuals with dementia and their families. In the past year, the FDA has approved two new drugs, Aduhelm and Leqembi, that target the buildup of amyloid beta plaques in the brain, a hallmark of Alzheimer's disease. While the approval of Aduhelm has been controversial, studies have shown that it can slow cognitive decline in certain patients. Clinical trials have also demonstrated that Leqembi can slow cognitive decline in individuals with mild to moderate Alzheimer's.

Experts emphasize that an early and accurate diagnosis is crucial, as it allows for a plan to be put in place to either treat or slow the progression of the disease. They recommend that individuals over the age of 65 consider a simple dementia screening, such as a mini cognitive assessment, to identify any potential issues and seek appropriate care.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
Early signs of dementia can include difficulty with language, such as word-finding problems, incorrect sentence construction, and trouble with self-expression. Changes in visual and spatial skills, like getting lost in previously familiar routes, can also be an early indicator. Personality and mood shifts without an underlying explanation are also red flags.
In recent years, the FDA has approved two new drugs, Aduhelm and Leqembi, that target the buildup of amyloid beta plaques in the brain, a hallmark of Alzheimer's disease. While the approval of Aduhelm has been controversial, studies have shown that it can slow cognitive decline in certain patients. Clinical trials have also demonstrated that Leqembi can slow cognitive decline in individuals with mild to moderate Alzheimer's.
Experts emphasize that an early and accurate diagnosis is crucial, as it allows for a plan to be put in place to either treat or slow the progression of the disease. They recommend that individuals over the age of 65 consider a simple dementia screening, such as a mini cognitive assessment, to identify any potential issues and seek appropriate care.

Read more news on

Healthside-arrow

Advertisement

Advertisement

Advertisement

You may also like

Pregnant Model's Sudden Death Shakes Bhopal Fashion Scene

1 day ago • 23 reads

BioCryst Acquires Astria, Analysts Adjust Price Target

7 hours ago • 4 reads

article image

Amgen's Repatha Cuts Heart Attack Risk by 36% in Landmark Study

10 Nov • 14 reads

article image

Roche's Experimental MS Drug Succeeds in Late-Stage Trial

11 Nov • 5 reads

article image

Veteran Director's Advice Shapes Actor's Meaningful Film Choices

10 Nov • 12 reads

article image